drugset / Trial / NCT05322252

Simultaneous Mifepristone and Misoprostol Versus Misoprostol Alone for Induction of Labor of Nonviable Second Trimester Pregnancy: a Pilot Randomized Controlled Trial

NCT05322252

Phase 4 Completed 30 enrolled Washington University School of Medicine
RandomizedParallel-groupOpen-labelTreatment

Summary

When time allows, administration of mifepristone prior to second trimester induction of labor decreases total labor time. However, in the setting of many pregnancy complications, decreasing time from diagnosis of nonviable pregnancy to delivery is of utmost importance to decrease risk of maternal complications. Previous data has shown that total abortion time is longer in the group receiving mifepristone owing to the delay between mifepristone administration and initiation of misoprostol induction of labor. Thus, the investigators aim to investigate whether simultaneous mifepristone and misoprostol has benefits over misoprostol alone when labor induction of a nonviable second trimester cannot be delayed.

Timeline

Start
2022-07-01
Primary completion
2025-06-14
Completion
2025-07-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Mifepristone Small molecule 200 mg Oral
Background Misoprostol Other / unclassified